MaxCyte Q2 revenue $9.6M (+35% YoY); raises 2022 core revenue growth guidance to ~30%

MAXCYTE, INC.

2022-Q2 EPS reported -$0.12 revenue$21,195,100

Total revenue $9.6M (+35% YoY); core business revenue +45% led by cell therapy +61%.
Net loss $8.3M (vs $4.4M loss Q2 2021); operating expenses $17.2M (up from $10.7M).
Cash & investments $240.9M as of June 30, 2022.
Raised 2022 core revenue growth guidance to ~30%; SPL program-related revenue expected ~$4M.
Signed 17th SPL agreement in July 2022 with LG Chem.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.